Lake Street Maintains Buy on Checkpoint Therapeutics, Lowers Price Target to $16
Portfolio Pulse from Benzinga Newsdesk
Lake Street analyst Thomas Flaten maintains a Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) but lowers the price target from $22 to $16.
May 30, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lake Street analyst maintains Buy rating on Checkpoint Therapeutics (NASDAQ:CKPT) but lowers price target from $22 to $16.
The news directly mentions Checkpoint Therapeutics (NASDAQ:CKPT) and the lowered price target by Lake Street analyst Thomas Flaten. While the Buy rating is maintained, the lower price target may create mixed sentiment among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100